Lesaffre has acquired Recombia Biosciences, a San Francisco Bay Area based biotechnology company centered on technology licensed from Stanford University, according to a release.
The acquisition builds on the strategic partnership created between the companies in 2020 to heighten Recombia Biosciences’ genome-editing technologies and further the development of yeasts for the sustainable production of fermented ingredients. The collaboration marked Lesaffre’s first step into the Synthetic Biology world.
Throughout the partnership, the companies have joined forces to create and develop new yeast strains and optimize the production of various biosourced ingredients and biofuels.
“From our very first discussions, we have shared a common vision of how our respective strengths could synergize and create new opportunities. We are very excited to be joining Lesaffre and are looking forward to addressing challenges together with new and innovative fermentation solutions,” said Bob St.Onge, Recombia’s COO.
The acquisition is a piece of Lesaffre’s comprehensive strategy to heavily invest in research and development to reach the greatest potential of microorganisms like yeast and beneficial bacteria.
“With the acquisition of Recombia Biosciences, we are enriching the group’s portfolio of cutting-edge technologies to accelerate innovation in yeast development and production, and we are surrounding ourselves with new talent that we warmly welcome. Innovation is part of Lesaffre’s DNA. This acquisition is a perfect illustration of Lesaffre’s mission: working together to better nourish and protect the planet,” said Brice-Audren Riché, CEO of Lesaffre.
Next Steps for Recombia Biosciences
Recombia Biosciences will be connected to the Lesaffre Bioengineering Center of Excellence. The company will remain as Recombia Biosciences as it continues to expand at its Brisbane, California location.
“This acquisition represents a cornerstone on our joint mission to generate the world’s most advanced microorganisms for industrial manufacturing. Becoming part of the Lesaffre family will further allow us to build on our successful foundation of sharing knowledge, technologies and expertise. Having collaborated with Lesaffre for over 10 years, I am particularly proud of this accomplishment, and I am excited about the opportunities that advanced genome engineering affords in biotechnology,” shared Lars Steinmetz, Recombia’s chairman of the board.
Read More:
New Collaboration Offers Innovative and Sustainable Farming Solutions
Kynetec Acquires Spark in Brazil
New Syngenta Italian Innovation Hub Inaugurated in Milan
Research Network to Help UK Agri-Food Industry Reach Net Zero
